Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: flatsville who wrote (282)	2/18/2001 8:34:14 AM
From: Dorine Essey	Respond to of 340

Flatsville, And it's not too late to pick up more on the dips. I love this stock. It has been good to me. Dorine

To: flatsville who wrote (282)	7/13/2001 5:58:50 AM
From: Dorine Essey	Read Replies (1) \| Respond to of 340

Teva Pharmaceutical The Israeli drug firm impresses Hilary Thu close $63.34 Kramer of Cisneros Group, who said Up $1.05, 1.7% "Teva is the best way to play both 1.2 million shares generic and branded drugs," citing (TEVA) products such as multiple sclerosis drug Copaxone. David Maris of Credit . Suisse First Boston rates it a buy . with a 12-month target of $76. (END) DOW JONES NEWS 07-12-01 08:52 PM